Aktis Oncology (AKTS) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Aktis Oncology is the larger company by market cap ($1.00 billion vs $916.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | MLTX |
|---|---|---|
| Share price | $18.00 | $10.77 |
| Market cap | $1.00B | $916.60M |
| 1-day change | +0.78% | -1.64% |
| YTD return | — | -18.29% |
| 1-year return | — | +16.06% |
| 5-year return | — | +8.57% |
| EPS (TTM) | $-1.70 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.19 | $23.29 |
| 52-week low | $14.72 | $8.80 |
| Distance from 52-week high | -47.35% | -53.76% |
| Average volume | 370.56K | 1.43M |
| Shares outstanding | 53.75M | 85.11M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
AKTS vs MLTX FAQ
Which is bigger, Aktis Oncology or MoonLake Immunotherapeutics?
Aktis Oncology (AKTS) is larger, with a market capitalization of $1.00B compared with $916.60M for MoonLake Immunotherapeutics (MLTX).
Are Aktis Oncology and MoonLake Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.